Hualan Bio Announces Clinical Trial Approval for Recombinant Anti-PD-L1 and TGF-β Bispecific Fusion Protein Injection

Hualan Biological Engineering, Inc. announced on May 4th,Company's Participating CompanyHualan Genetic Engineering Co., Ltd.Hualan Genetic Engineering (Henan) Co., Ltd. (hereinafter referred to as "Hualan Genetic"), a wholly-owned subsidiary, has received the "Drug Clinical Trial Approval Notice" (Notice No.: 2023LP00781) issued by the National Medical Products Administration. The clinical trial application for the "Recombinant Anti-PD-L1 and TGF-β Dual-Function Fusion Protein Injection" submitted by Hualan Genetic has been approved: After review, the Recombinant Anti-PD-L1 and TGF-β Dual-Function Fusion Protein Injection submitted by Hualan Genetic meets the relevant requirements for drug registration, and it is agreed that this product will be used alone in the clinical trial for advanced recurrent or refractory malignant solid tumors. Hualan Genetic will carry out the relevant clinical trial work as soon as possible according to the requirements of the Drug Clinical Trial Approval Notice.